Novo Nordisk announced that the world's first oral glucagon-like peptide-1 receptor agonist (GLP-1RA) - Novoxin (semaglutide tablets) has been fully launched in China. With its convenient oral administration method, Novoxin helps patients benefit from GLP-1RA drugs earlier, helps achieve high-quality blood sugar targets and comprehensive metabolic management, and brings an innovative category to the clinical treatment of type 2 diabetes in China.